Welcome to our dedicated page for Beigene SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode the science-heavy language in BeiGene’s oncology disclosures? Each 10-K details dozens of global clinical trials, milestone obligations, and R&D burn-rates that can stretch past 300 pages. Finding when cash runs out—or which trial just moved to Phase III—takes time investors rarely have.
Stock Titan solves that problem. Our AI-powered summaries turn BeiGene SEC filings explained simply, highlighting the exact paragraph that answers questions like “How much did R&D rise this quarter?” or “Which licensing partner triggered a milestone?” Whether you need the BeiGene annual report 10-K simplified, a BeiGene quarterly earnings report 10-Q filing, or BeiGene 8-K material events explained, the platform delivers real-time alerts the moment they hit EDGAR. You’ll also see BeiGene Form 4 insider transactions real-time, complete with context so you understand why an executive sold shares before a data readout.
Dig deeper without getting lost: track BeiGene insider trading Form 4 transactions to spot buying trends, scan BeiGene proxy statement executive compensation to evaluate alignment, and run instant BeiGene earnings report filing analysis to compare pipeline spending quarter-over-quarter. From understanding BeiGene SEC documents with AI to monitoring BeiGene executive stock transactions Form 4, every filing type is covered and linked to the metrics that matter—so you make informed decisions faster.
Wu Xiaobin, President and COO of BeOne Medicines Ltd. (ONC), reported multiple transactions on 08/13/2025 and 08/14/2025 involving the company’s American Depositary Shares (ADS) and stock options. The filing states each ADS represents 13 ordinary shares. The reporting person sold multiple blocks of ADS under a Rule 10b5-1 trading plan adopted May 13, 2024 (amended May 14, 2025), with reported weighted-average sale prices ranging roughly from $300.00 to $308.12 across the transactions. The filing also shows a series of option grants/rights: 296,049, 352,105, 399,828, and 119,340 ordinary-share equivalents (various exercise prices and vesting schedules), and indicates direct and indirect ownership entries including shares held by the reporting person’s wife.
BeOne Medicines reporting person Henry Lee (SVP, General Counsel and Director) disclosed multiple ADS and option transactions on 08/13/2025. The filing shows several sales of American Depositary Shares under a Rule 10b5-1 plan adopted May 14, 2025, including disposals at weighted-average prices of $300 and $301.00 per ADS and a separate sale at $300.1858. The report also records acquisitions of ADS at prices of $194.47 and $159.03 and net changes in ordinary shares reflecting ADS conversions (1 ADS = 13 ordinary shares). Two option grants (or holdings) remain outstanding with exercise prices of $14.96 and $12.23 covering 56,953 and 50,037 ordinary shares respectively, and vesting schedules described in the filing.
BeOne Medicines Ltd. (ONC) submitted a Form 144 proposing the sale of 89,794 ADS through Morgan Stanley Smith Barney LLC on NASDAQ, showing an aggregate market value of $25,869,651.40 and 54,564,278 ADS outstanding. The approximate sale date is 08/13/2025.
The filing states the ADS were acquired on 08/13/2025 by exercise of stock options from the issuer and paid in cash. It also lists prior common-share sales by Xiaobin Wu in June 2025: 1,363 (6/23/2025) for $354,380.00, 630 (6/17/2025) for $158,047.22, 1,543 (6/16/2025) for $409,694.43, and 1,934 (6/06/2025) for $489,590.94. The notice includes the standard representation that the filer does not possess undisclosed material adverse information.
BeOne Medicines Ltd. (ONC) filed a Form 144 disclosing a proposed sale of 10,338 ADS on NASDAQ with an aggregate market value of $2,978,377.80. The filing shows those ADS were acquired partly by an exercise of stock options (9,226 ADS, cash paid on 08/13/2025) and partly as restricted stock units (1,112 ADS on 06/05/2025). The notice lists 54,564,278 shares outstanding, and the proposed block represents a very small portion of outstanding shares.
The filing also discloses recent sales by the same seller over the past three months: 2,042 common shares sold on 07/30/2025, 06/16/2025 and 06/06/2025 for combined gross proceeds of $571,975.61. This Form 144 is a regulatory notice of intent to sell and records the means of acquisition and prior dispositions.
BeOne Medicines (ONC) – Form 4 insider activity
Chief Financial Officer Aaron Rosenberg reported a mandatory tax-related sale of 1,190 American Depositary Shares (ADS) on 08/01/2025 at $290.47 per ADS, generating roughly $0.35 million in proceeds. Each ADS represents 13 ordinary shares. The disposition was executed automatically to cover withholding taxes triggered by the vesting of a restricted share-unit (RSU) grant. One-quarter of the RSU award vests annually on 31 July through 2028, with accelerated vesting possible upon certain termination events.
No derivative securities were exercised or disposed of in this filing. After the transaction, Rosenberg directly owns 215,332 ordinary shares and 0 ADS, meaning the shares sold equal about 7 % of his reported equity stake. The filing shows continued equity alignment through ongoing RSU vesting, while the share sale itself may be viewed as a routine liquidity event rather than an indicator of fundamental outlook.
BeOne Medicines Ltd. (ONC) – Form 4 filing dated 31-Jul-2025
SVP & General Counsel Henry Chan Lee reported a mandatory tax-related sale of 920 American Depositary Shares (ADS) on 30-Jul-2025 at a weighted-average price of $304.6008. Each ADS equals 13 ordinary shares, so the transaction represents the disposition of roughly 11,960 ordinary shares equivalent.
The ADS were automatically sold to cover withholding taxes upon vesting of a previously granted RSU award that vests 25 % annually on the anniversary of 29-Jul-2022, with possible acceleration on certain termination events. Following the sale, Lee continues to hold 266,474 ordinary shares directly.
- No derivative security activity was reported.
- The filing was executed by attorney-in-fact Qing Nian.
The transaction appears routine and driven by tax-withholding obligations rather than discretionary selling, limiting its market significance.
FAQ
What is the current stock price of Beigene (ONC)?
What is the market cap of Beigene (ONC)?
